vs
Side-by-side financial comparison of COHEN & STEERS, INC. (CNS) and Vericel Corp (VCEL). Click either name above to swap in a different company.
COHEN & STEERS, INC. is the larger business by last-quarter revenue ($143.8M vs $92.9M, roughly 1.5× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 24.3%, a 0.8% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 2.9%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $-126.4M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 8.3%).
Cohen & Steers is an American investment management company. It focuses on investments in real estate securities via real estate investment trusts (REIT) and alternative income via preferred securities.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
CNS vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $143.8M | $92.9M |
| Net Profit | $34.9M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 28.0% | 24.1% |
| Net Margin | 24.3% | 25.0% |
| Revenue YoY | 2.9% | 23.3% |
| Net Profit YoY | -23.9% | 17.3% |
| EPS (diluted) | $0.67 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $143.8M | $92.9M | ||
| Q3 25 | $141.7M | $67.5M | ||
| Q2 25 | $136.1M | $63.2M | ||
| Q1 25 | $134.5M | $52.6M | ||
| Q4 24 | $139.8M | $75.4M | ||
| Q3 24 | $133.2M | $57.9M | ||
| Q2 24 | $121.7M | $52.7M | ||
| Q1 24 | $122.7M | $51.3M |
| Q4 25 | $34.9M | $23.2M | ||
| Q3 25 | $41.7M | $5.1M | ||
| Q2 25 | $36.8M | $-553.0K | ||
| Q1 25 | $39.8M | $-11.2M | ||
| Q4 24 | $45.8M | $19.8M | ||
| Q3 24 | $39.7M | $-901.0K | ||
| Q2 24 | $31.8M | $-4.7M | ||
| Q1 24 | $34.0M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 28.0% | 24.1% | ||
| Q3 25 | 34.5% | 5.1% | ||
| Q2 25 | 31.8% | -3.2% | ||
| Q1 25 | 33.6% | -24.3% | ||
| Q4 24 | 35.3% | 24.5% | ||
| Q3 24 | 33.7% | -4.3% | ||
| Q2 24 | 31.5% | -11.5% | ||
| Q1 24 | 32.8% | -10.7% |
| Q4 25 | 24.3% | 25.0% | ||
| Q3 25 | 29.4% | 7.5% | ||
| Q2 25 | 27.1% | -0.9% | ||
| Q1 25 | 29.6% | -21.4% | ||
| Q4 24 | 32.8% | 26.3% | ||
| Q3 24 | 29.8% | -1.6% | ||
| Q2 24 | 26.1% | -8.9% | ||
| Q1 24 | 27.7% | -7.5% |
| Q4 25 | $0.67 | $0.46 | ||
| Q3 25 | $0.81 | $0.10 | ||
| Q2 25 | $0.72 | $-0.01 | ||
| Q1 25 | $0.77 | $-0.23 | ||
| Q4 24 | $0.89 | $0.40 | ||
| Q3 24 | $0.77 | $-0.02 | ||
| Q2 24 | $0.63 | $-0.10 | ||
| Q1 24 | $0.68 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $145.5M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $562.0M | $354.6M |
| Total Assets | $876.7M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $145.5M | $137.5M | ||
| Q3 25 | $98.1M | $135.4M | ||
| Q2 25 | $95.4M | $116.9M | ||
| Q1 25 | $65.2M | $112.9M | ||
| Q4 24 | $183.0M | $116.2M | ||
| Q3 24 | $106.5M | $101.7M | ||
| Q2 24 | $122.0M | $102.5M | ||
| Q1 24 | $99.5M | $110.6M |
| Q4 25 | $562.0M | $354.6M | ||
| Q3 25 | $550.3M | $321.9M | ||
| Q2 25 | $528.5M | $306.8M | ||
| Q1 25 | $507.7M | $295.5M | ||
| Q4 24 | $511.7M | $292.0M | ||
| Q3 24 | $491.0M | $257.5M | ||
| Q2 24 | $463.2M | $243.0M | ||
| Q1 24 | $378.9M | $233.9M |
| Q4 25 | $876.7M | $488.0M | ||
| Q3 25 | $801.6M | $453.3M | ||
| Q2 25 | $751.0M | $435.6M | ||
| Q1 25 | $834.9M | $424.6M | ||
| Q4 24 | $812.4M | $432.7M | ||
| Q3 24 | $727.8M | $390.4M | ||
| Q2 24 | $784.1M | $376.8M | ||
| Q1 24 | $680.7M | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-120.4M | $15.0M |
| Free Cash FlowOCF − Capex | $-126.4M | $12.8M |
| FCF MarginFCF / Revenue | -87.9% | 13.8% |
| Capex IntensityCapex / Revenue | 4.2% | 2.4% |
| Cash ConversionOCF / Net Profit | -3.45× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-253.6M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-120.4M | $15.0M | ||
| Q3 25 | $55.1M | $22.1M | ||
| Q2 25 | $-67.6M | $8.2M | ||
| Q1 25 | $-108.9M | $6.6M | ||
| Q4 24 | $96.7M | $22.2M | ||
| Q3 24 | $25.6M | $10.2M | ||
| Q2 24 | $31.4M | $18.5M | ||
| Q1 24 | $4.9M | $7.2M |
| Q4 25 | $-126.4M | $12.8M | ||
| Q3 25 | $52.6M | $19.5M | ||
| Q2 25 | $-69.8M | $81.0K | ||
| Q1 25 | $-110.0M | $-7.6M | ||
| Q4 24 | $85.0M | $8.5M | ||
| Q3 24 | $24.2M | $-9.2M | ||
| Q2 24 | $27.1M | $1.8M | ||
| Q1 24 | $537.0K | $-6.8M |
| Q4 25 | -87.9% | 13.8% | ||
| Q3 25 | 37.1% | 28.8% | ||
| Q2 25 | -51.3% | 0.1% | ||
| Q1 25 | -81.8% | -14.5% | ||
| Q4 24 | 60.8% | 11.2% | ||
| Q3 24 | 18.2% | -15.9% | ||
| Q2 24 | 22.3% | 3.4% | ||
| Q1 24 | 0.4% | -13.3% |
| Q4 25 | 4.2% | 2.4% | ||
| Q3 25 | 1.8% | 3.9% | ||
| Q2 25 | 1.6% | 12.9% | ||
| Q1 25 | 0.8% | 27.0% | ||
| Q4 24 | 8.3% | 18.3% | ||
| Q3 24 | 1.1% | 33.5% | ||
| Q2 24 | 3.5% | 31.8% | ||
| Q1 24 | 3.5% | 27.3% |
| Q4 25 | -3.45× | 0.65× | ||
| Q3 25 | 1.32× | 4.35× | ||
| Q2 25 | -1.84× | — | ||
| Q1 25 | -2.74× | — | ||
| Q4 24 | 2.11× | 1.12× | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 0.99× | — | ||
| Q1 24 | 0.14× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CNS
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
